Continuous IV Deferoxamine for Chronic Iron Overload in Patients Undergoing Hemodialysis by Home Parenteral Therapy: A Case Report and Literature Review.
作者信息
Lau Huisun, Huang Eddie, Olatunbosun Caitlin
机构信息
, PharmD, is with the Home Parenteral Therapy Program, Alberta Health Services, Edmonton, Alberta.
, BSP, ACPR, MPH, is with Pharmacy Services, Alberta Health Services, Edmonton, Alberta.
出版信息
Can J Hosp Pharm. 2024 Oct 9;77(4):e3577. doi: 10.4212/cjhp.3577. eCollection 2024.
Abstract
摘要
相似文献
1
Continuous IV Deferoxamine for Chronic Iron Overload in Patients Undergoing Hemodialysis by Home Parenteral Therapy: A Case Report and Literature Review.持续静脉输注去铁胺用于接受家庭肠外治疗的血液透析患者慢性铁过载：一例报告及文献综述
Can J Hosp Pharm. 2024 Oct 9;77(4):e3577. doi: 10.4212/cjhp.3577. eCollection 2024.
2
Intraperitoneal deferoxamine therapy for iron overload in children undergoing CAPD.
Kidney Int. 1989 Jun;35(6):1330-5. doi: 10.1038/ki.1989.131.
3
Iron overload and mobilization in long-term hemodialysis patients.
Am J Kidney Dis. 1987 Oct;10(4):293-9. doi: 10.1016/s0272-6386(87)80025-2.
4
5
Serum bactericidal activity for Yersinia enterocolitica in hemodialysis patients: effects of iron overload and deferoxamine.血液透析患者血清对小肠结肠炎耶尔森菌的杀菌活性：铁过载和去铁胺的影响
Am J Kidney Dis. 1992 Feb;19(2):144-8. doi: 10.1016/s0272-6386(12)70123-3.
6
Reduction in liver iron in hemodialysis patients with transfusional iron overload by deferoxamine mesylate.
Am J Kidney Dis. 1988 Jul;12(1):40-4. doi: 10.1016/s0272-6386(88)80070-2.
7
Iron overload and iron chelating agent exposure in anemia-associated outer retinal degeneration: a case report and review of the literature.铁过载和铁螯合剂暴露与贫血相关性外层视网膜变性：病例报告及文献复习。
BMC Ophthalmol. 2021 Jul 13;21(1):277. doi: 10.1186/s12886-021-02030-1.
8
Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload.
Blood. 2000 May 1;95(9):2776-9.
9
Failure of deferoxamine to improve iron overload in chronic hemodialysis patients.
Int J Artif Organs. 1990 Apr;13(4):211-7.
10
Deferasirox.地拉罗司
Am J Health Syst Pharm. 2007 Mar 15;64(6):606-16. doi: 10.2146/ajhp060405.
本文引用的文献
1
Effect of deferoxamine therapy on insulin resistance in end-stage renal disease patients with iron overload.去铁胺疗法对铁过载的终末期肾病患者胰岛素抵抗的影响。
Saudi J Kidney Dis Transpl. 2014 Jul;25(4):808-13. doi: 10.4103/1319-2442.135025.
2
3
Low dose desferrioxamine can improve erythropoiesis in iron-overload hemodialysis patients without side effects.低剂量去铁胺可改善铁过载血液透析患者的红细胞生成，且无副作用。
Ren Fail. 1999 Nov;21(6):665-73. doi: 10.3109/08860229909094160.
4
5
Iron overload and mobilization in long-term hemodialysis patients.
Am J Kidney Dis. 1987 Oct;10(4):293-9. doi: 10.1016/s0272-6386(87)80025-2.
6
Reduction in liver iron in hemodialysis patients with transfusional iron overload by deferoxamine mesylate.
Am J Kidney Dis. 1988 Jul;12(1):40-4. doi: 10.1016/s0272-6386(88)80070-2.
7
Improvement in the erythropoiesis of chronic haemodialysis patients with desferrioxamine.
Lancet. 1988 May 7;1(8593):1009-11. doi: 10.1016/s0140-6736(88)91839-9.
8
Failure of deferoxamine to improve iron overload in chronic hemodialysis patients.
Int J Artif Organs. 1990 Apr;13(4):211-7.
9
Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload.
Scand J Urol Nephrol Suppl. 1990;131:49-54.
10
Hemosiderosis in a patient on regular hemodialysis: treatment by desferrioxamine.
Clin Nephrol. 1976 Jul;6(1):326-8.
Zotero 插件